Sclerostin linked to vascular disease in type 2 diabetes

January 28, 2013
Sclerostin linked to vascular disease in type 2 diabetes
Circulating levels of the Wnt/β-catenin signaling inhibitor sclerostin are higher in patients with type 2 diabetes who also have atherosclerotic disease, according to a study published online Jan. 3 in Diabetes Care.

(HealthDay)—Circulating levels of the Wnt/β-catenin signaling inhibitor sclerostin are higher in patients with type 2 diabetes who also have atherosclerotic disease, according to a study published online Jan. 3 in Diabetes Care.

Noting that Wnt/β-catenin signaling is related to the pathology of various diseases, Sonia Morales-Santana, Ph.D., from the Hospital Universitario San Cecilio in Granada, Spain, and colleagues measured serum sclerostin levels in 78 patients with mellitus, of whom 44 had atherosclerotic disease.

The researchers found that patients with atherosclerotic disease had significantly higher serum sclerostin levels, with a 4 percent increase in the risk of atherosclerotic disease for each 1 pmol/L increase in sclerostin. A sclerostin cut-off of 42.3 pmol/L could detect an increased risk of atherosclerotic disease with a sensitivity of 69 percent and a specificity of 54.8 percent. Higher sclerostin levels were associated with abnormal intima-media thickness and aortic calcification in both men and women, and with carotid plaques in men only. Homocysteine levels and intima-media thickness were positively correlated with sclerostin.

"Circulating sclerostin is increased in patients with ," Morales-Santana and colleagues conclude.

Explore further: Even minor physical activity may benefit bone health in premenopausal women

More information: Abstract
Full Text (subscription or payment may be required)

Related Stories

Cadmium linked to plaque development in older women

July 31, 2012

(HealthDay) -- Cadmium levels in blood and urine are independently associated with the development of atherosclerotic plaques in older women, according to a study published online July 20 in the Journal of Internal Medicine.

Fetuin-A levels linked to cardiovascular disease risk

January 8, 2013

(HealthDay)—In elderly individuals without type 2 diabetes, high levels of fetuin-A, a protein that inhibits arterial calcification and insulin action, is associated with a lower risk of cardiovascular disease, according ...

Long-term cardiac effects for childhood cancer survivors

March 7, 2012

(HealthDay) -- Regardless of exposure to cardiotoxic cancer therapies, survivors of childhood cancers display cardiovascular abnormalities and have markers of increased systemic inflammation and atherosclerotic disease, according ...

Aspirin enhances platelet isoprostanes in type 2 diabetes

March 23, 2012

(HealthDay) -- For patients with type 2 diabetes mellitus (T2DM) who are treated with aspirin, isoprostanes are overproduced, which is linked with enhanced platelet recruitment, according to a study published online March ...

Recommended for you

Post-biotics may help shield obese from diabetes

April 20, 2017

You've heard of pre-biotics and pro-biotics, but now you'll be hearing a lot more about post-biotics. Researchers at McMaster University have begun to identify how post-biotics, or the by-products of bacteria, lower blood ...

Diabetes continues its relentless rise

April 13, 2017

(HealthDay)—Two new studies on diabetes deliver good and bad news, but the overall message is that the blood sugar disease remains a formidable public health burden.

Researchers unravel how stevia controls blood sugar levels

April 11, 2017

What makes stevia taste so extremely sweet? And how does the sweetener keep our blood sugar level under control? Researchers at KU Leuven (University of Leuven, Belgium) have discovered that stevia stimulates a protein that ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.